J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent

June 04, 2025 11:49 AM PDT | By EODHD

Google News:

J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent — Image source: Kalkine Media

Recent News

Kalkine Valens Semiconductor Joins NYSE Composite Amid Rising Sector A...

Kalkine FinVolution Group’s Role in the NYSE Composite Landscape

CoreCard Co. Listed in Russell 1000 Index by Kalkine

S&P 500 Chart with Kalkine Key Trends and Market Movements

[On a white surface are pills and torn paper with the inscription - ULCERATIVE COLITIS] Despite premarket gains, shares of AnaptysBio (NASDAQ:ANAB [https://seekingalpha.com/symbol/ANAB]) turned lower on Wednesday following disappointing mid-stage trial data for Johnson & Johnson’s (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) anti-inflammatory agent JNJ-67484703, designed similar to ANAB’s lead asset rosnilimab. An abstract released ahead of a European medical event on rheumatology indicated on Wednesday that JNJ-67484703, which targets the T cell receptor PD-1, appeared safe and well-tolerated in a Phase 2 trial. While the open-label study involved patients with autoimmune disorders, rheumatoid arthritis, ulcerative colitis, and Sjogren’s disease, the investigators had to discontinue [https://distribution-congress.eular.org/from.storage?image=382xVqPluwnOrBoZFqVPTwuRsEjspEZuD4M0iFMf47K8rMwO0qfRJnlZw-nakUlz0] the trial’s UC arm due to slow recruitment and high withdrawal rate. San Diego, California-based AnaptysBio (NASDAQ:ANAB [https://seekingalpha.com/symbol/ANAB]) announced encouraging long-term data from a Phase 2 trial for its PD-1-targeting anti-inflammatory agent rosnilimab on Tuesday, sending its shares higher in the post-market trading. Concurrently, the company reaffirmed plans to release initial data from a Phase 2 trial for rosnilimab in ulcerative colitis in Q4 2025.

[https://seekingalpha.com/news/4455376-anaptys-stock-gains-arthritis-drug-data] MORE ON ANAPTYSBIO, J&J * Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market [https://seekingalpha.com/article/4791198-johnson-and-johnson-relative-stability-in-wild-2025-stock-market] * Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript) [https://seekingalpha.com/article/4790594-johnson-and-johnson-jnj-presents-at-the-bernsteins-41st-annual-strategic-decisions-conference] * Johnson & Johnson: Dividend King On Sale Yielding Over 3% And Undervalued [https://seekingalpha.com/article/4789692-johnson-and-johnson-dividend-king-on-sale-yielding-over-3-percent-and-undervalued] * Anaptys gains after updated data from mid-stage trial for arthritis therapy [https://seekingalpha.com/news/4455376-anaptys-stock-gains-arthritis-drug-data] * J&J posts late-stage trial win for PARP inhibitor combo in prostate cancer [https://seekingalpha.com/news/4454913-jj-wins-phase-3-trial-prostate-cancer-dru]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.